Efficacy of Rapid Treatment Initiation Following Primary Toxoplasma gondii Infection During Pregnancy
Open Access
- 29 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 54 (11), 1545-1552
- https://doi.org/10.1093/cid/cis234
Abstract
Background. Treatment of Toxoplasma gondii infection acquired during pregnancy differs in many countries. In Germany, spiramycin is given until the 16th week of pregnancy, followed by at least 4 weeks of combination therapy with pyrimethamine, sulfadiazine, and folinic acid independent of the infection stage of the fetus. If infection of the fetus is confirmed by polymerase chain reaction or if fetal ultrasound indicates severe symptoms (hydrocephalus, ventricular dilation), treatment is continued until delivery with regular monitoring of pyrimethamine and sulfadiazine concentration in maternal blood and observation of possible adverse effects. In other European countries, such as France, only spiramycin is given unless infection of the fetus is proven. Methods. To evaluate the effectiveness of the German treatment scheme, a retrospective analysis of 685 women who showed a serological constellation consistent with primary infection in pregnancy and their children was performed. Results. We found an increased transmission rate to the fetus with increased time in gestation and a decreased risk of clinical manifestations. In comparison with studies performed in other countries, the overall transmission rate (4.8%) and the rate of clinical manifestations in newborns (1.6%) were lower. Conclusions. Use of spiramycin from time of diagnosis of acute acquisition of infection by the pregnant woman until week 16, followed by pyrimethamine, sulfadiazine, and folinic acid for at least 4 weeks in combination with a standardized follow-up program is efficient in reducing transplacental transmission of the parasite and the burden of disease in the newborn.Keywords
This publication has 16 references indexed in Scilit:
- Toxoplasmose et grossesseJournal Français d'Ophtalmologie, 2010
- What Do We Know About Risk Factors for Infection in Humans withToxoplasma gondiiand How Can We Prevent Infections?Zoonoses and Public Health, 2010
- Clinical Practice: Management ofToxoplasma gondiiInfection during PregnancyClinical Infectious Diseases, 2008
- Disease Burden of Congenital ToxoplasmosisClinical Infectious Diseases, 2007
- Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' dataThe Lancet, 2007
- Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: A cohort study in 13 European centresActa Paediatrica, 2005
- Congenital Toxoplasmosis: Efficacy of Maternal Treatment with Spiramycin AloneAmerican Journal of Reproductive Immunology, 1998
- Classification system and case definitions ofToxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspringEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996
- Congenital toxoplasmosis: 10-year follow upEuropean Journal of Pediatrics, 1995
- Recognition of Different Toxoplasma Antigens by IgM and IgG Antibodies in Mothers and Their Congenitally Infected NewbornsThe Journal of Infectious Diseases, 1985